Bowel Preparation May Lead to a Higher Feasibility of Intestinal Infection
Bowel Preparation for Colonoscopy May Lead to a Higher Feasibility of Intestinal Infection: a Clinical and Basic Research
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Early Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients who agree to participant in the study
Exclusion Criteria:
- patients who couldn't stand polyethyleneglycol or inulin patients couldn't provide Informed consent patients who are suffering from sever heart disease, pulmonary disease or renal dysfunction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: polyethyleneglycol only
participants take 2L of polyethyleneglycol only
|
2L of polyethyleneglycol
|
|
Experimental: polyethyleneglycol puls Inulin
participants take 2L of polyethyleneglycol, subsequently take 15g inulin per day.
|
2L of polyethyleneglycol
15g inulin per day
|
|
Experimental: polyethyleneglycol puls probiotic combination product
Participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day.
The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.
|
2L of polyethyleneglycol
participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day.
The probiotic combination product, named "Mei Ri Yi Jun" was produced by Wedge Pharmaceuticals.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Polyethyleneglycol could lead to changes in the intestinal flora
Time Frame: one year(from 15/3/2022 to 15/3/2023)
|
People with polyethyleneglycol administration will lead to a decrease of intestinal flora quantity
|
one year(from 15/3/2022 to 15/3/2023)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
inulin and probiotics could improve the recovery of gut microbiota
Time Frame: one year(from 15/3/2022 to 15/3/2023)
|
inulin and probiotics will improve the recovery of flora quantity after Polyethyleneglycol administration
|
one year(from 15/3/2022 to 15/3/2023)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guanjun Kou, Qilu Hospital of Shandong University
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-SDU-QILU-088
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.